AstraZeneca Plc on Sunday said it had conducted a review of people vaccinated with its COVID-19 vaccine which has shown no evidence of an increased risk of blood clots.
The statement by the company said that a careful review of all available safety data of more than 17 million people vaccinated in the European Union and UK with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country.
According to a report by Global News, it has reached out to see if Health Canada was considering halting its AstraZeneca vaccine rollout or had requested any additional data from its clinical trials, but did not get an immediate response.
